Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
Completed
- Conditions
- Non-squamous NSCLC
- Registration Number
- NCT05261438
- Lead Sponsor
- Hunan Province Tumor Hospital
- Brief Summary
This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.
- Detailed Description
This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
18，Advanced Metastatic Non-squamous NSCLC Treatment Plan is atezolizumab-bevacizumab-carboplatin-paclitaxel
Exclusion Criteria
Patients with contraindication of chemotherapy Pregnant or breast feeding women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS September 2019- september 2021 progression-free survival
OS September 2019- september 2021 overall survival
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hunan Cancer Hospital
🇨🇳Changsha, Hunan, China